<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217617</url>
  </required_header>
  <id_info>
    <org_study_id>GIMI-IRB-17014</org_study_id>
    <nct_id>NCT03217617</nct_id>
  </id_info>
  <brief_title>Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector （TYF-IL-2Rg）</brief_title>
  <official_title>Gene Transfer for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self-inactivating Lentiviral Vector （TYF-IL-2Rg）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Geno-Immune Medical Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Geno-Immune Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II clinical trial of gene transfer for treating X-linked severe combined
      immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector TYF-IL-2Rg to
      functionally correct the defective gene(s). The primary objectives are to evaluate the safety
      and efficacy of the gene transfer clinical protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      X-linked severe combined immunodeficiency (SCID-X1) is a genetic disorder caused by defects
      in the common cytokine receptor chain, normally on the surface of lymphocytes. Individuals
      with SCID-X1 lack the normal development of a functional immune system and so have difficulty
      fighting infections, which may lead to chronic or severe illness and death. X-SCID patients
      are normally rescued by a bone marrow transplant from a healthy donor. This trial aims to
      treat SCID-X1 using a self-inactivating lentiviral vector carrying a functional gene to
      correct the genetic defect. By collecting an individual's stem cells and modifying them with
      a lentivirus, the gene-corrected cells can be returned into the blood to help produce normal
      healthy immune cells.

      The primary objectives are to evaluate the safety of the self-inactivating lentiviral vector
      TYF-IL-2Rg, the ex vivo gene transfer clinical protocol and the efficacy of immune
      reconstitution in patients overcoming frequent infections present at the time of treatment,
      assessment of integration sites, and finally the long-term correction of immunodeficiency.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall immune reconstitution</measure>
    <time_frame>1 year</time_frame>
    <description>T and B cell recovery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of infection status</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>SCID, X Linked</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gene transfer to treat SCID-X1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TYF-IL-2Rg gene-modified autologous stem cells</intervention_name>
    <description>Infusion of transduced autologous stem cells</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of classical SCID-X1 based on:

               -  A proven mutation in the common gamma chain gene as defined by direct sequencing
                  of patient DNA.

               -  T-cell immune deficiency defined as one or more of the following: CD3+ autologous
                  T cells &lt; 300/ul, or less than 50% of normal value for in vitro mitogen
                  stimulation, or absent proliferation in vitro to antigens.

          2. With severe infections, including but not limited to: pneumonitis; protracted diarrhea
             requiring total parenteral nutrition; infection with herpes viruses or adenovirus or
             fungus; disseminated BCG infection.

          3. No cytogenetic abnormalities (medullary karyotype) and no detection of main
             rearrangements associated with acute leukemia of children.

          4. No prior allogeneic stem cell transplantation.

          5. Life expectancy ≥ 2 months.

          6. Negative for HIV infection.

          7. Written, informed consent obtained prior to any study-specific procedures.

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lung-Ji Chang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenzhen Geno-Immune Medical Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiao-Dong Shi, M.D./Ph. D</last_name>
    <role>Study Director</role>
    <affiliation>Capital Institute of Pediatrics affiliated Children's hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Zheng, M.D./Ph. D</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lung-Ji Chang, Ph.D</last_name>
    <phone>86-075586725195</phone>
    <email>c@szgimi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Capital Institute of Pediatrics affiliated Children's hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XiaoDong Shi, M.D./P.H.D</last_name>
      <phone>+86-13911601076</phone>
      <email>xsusan28@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Lixiao Shi, M.M.</last_name>
      <phone>+86-18810963129</phone>
      <email>13780524314@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Zheng, MD/PhD</last_name>
      <phone>+86-13683284467</phone>
      <email>cutezjie@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Geno-immune Medical Institute</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lung-Ji Chang, PhD</last_name>
      <phone>86-075586725195</phone>
      <email>c@szgimi.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2017</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shenzhen Geno-Immune Medical Institute</investigator_affiliation>
    <investigator_full_name>Lung-Ji Chang</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>SCID-X1</keyword>
  <keyword>lentiviral vector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>X-Linked Combined Immunodeficiency Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

